OBJECTIVES: Examine improvement in physical function, HRQOL&work productivity in a subset of Asian patients from the golimumab(GLM) RA&AS trials. METHODS: RA patients with inadequate response to MTX in GO-FORWARD(N=444)&AS patients despite NSAID/DMARDs in GO-RAISE(N=356) were randomized to SC GLM(50or100mg) or placebo q4wks. At wk16, RA patients with <20% improvement in tender&swollen joint count or AS patients with <20% improvement in both total back pain&morning stiffness entered early escape(i.e.,placebo received GLM 50mg&GLM 50 mg received GLM 100mg).Physical function was assessed using HAQ(0-3) in RA&BASFI (0-10) in AS. HRQOL was assessed using SF-36 PCS(0-100)&SF-36 MCS(0-100). Impact of disease on work productivity was assessed using a productivity VAS(0-10). Clinically meaningful improvement was defined as improvement of ≥0.25 point in HAQ, ≥2 points in BASFI or ≥5 points in SF-36 PCS&MCS. RESULTS: At baseline, RA patients(N=48) had a mean HAQ score of 1.35,&AS patients(N=83) had a mean BASFI score of 3.25; PCS&MCS were 31.5& 42.5, respectively, in RA, &33.2&41.3 in AS; productivity VAS was 5.6 in RA&AS. Compared to placebo+MTX-treated RA patients(N=22), GLM+MTX-treated patients (N=26) had greater mean improvement in HAQ(0.54vs-0.01, p<0.01), PCS(7.9 vs -0.40, p<0.01)&work productivity(-2.4 vs-0.4, p<0.05), the change in MCS was not statistically significant(3.0vs2.1, p>0.05).  Compared to placebo-treated AS patients(N=17), GLM-treated patients(N=66) had greater mean improvements in BASFI(1.51vs0.28, p=0.05), MCS(5.3vs-1.1, p<0.05)&work productivity(-2.9vs-0.9, p<0.05); change in PCS was not statistically significant(9.0vs5.7,p>0.05). Greater proportions of RA patients in GLM group than placebo achieved clinically meaningful improvement in HAQ(73.1%vs30%, p<0.01), PCS(61.5%vs25%, p=0.01)&MCS(50%vs35%,p=0.31); in AS, similar trends in clinically meaningful improvement in BASFI, PCS&MCS observed between groups. Improvements in HAQ, BASFI, SF-36&work productivity in GLM-treated patients were sustained over wk52 and 104, &were consistent across populations (Asia vs non-Asia). CONCLUSIONS: Patients from Asia with RA or AS treated with GLM demonstrated improved physical function&HRQOL.